https://aseestant.ceon.rs/index.php/scriptamed/issue/feed Scripta Medica 2025-03-12T21:57:48+01:00 Miloš P. Stojiljković mpstojiljkovic@gmail.com SCIndeks Assistant <p><em>Scripta Medica</em> is a peer-reviewed and open access journal available in the online and printed form. It covers all fields of medicine, dental medicine, pharmacy and health sciences. <em>Scripta Medica</em> is being published quarterly, by the end of each quarter. The journal has the International Advisory Board with memebers from all over the world.</p> https://aseestant.ceon.rs/index.php/scriptamed/article/view/52822 Assessing the Efficacy of Methanol Extracts of Ocimum Sanctum Linn. and Ocimum Basilicum Linn. in Diabetic Neuropathy 2025-03-12T21:57:48+01:00 Shabeena Khan shabeenasabbir@gmail.com Abhishek Bhanot dravbhanot@gmail.com Divya Dhawal Bhandari nainagumber@gmail.com <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Background/Aim:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Our nerves can be impacted by thousands of diseases and ailments, but diabetes-related neuropathy is the name given to the endocrine system issue that results in nerve damage. Herbal plants having antioxidant activity play an important role in managing diabetes and the associated complications. <em>Ocimum sanctum</em> and <em>Ocimum basilicum </em>plants have shown antihyperglycemic as well as neuroprotective activity but the effect of <em>Ocimum sanctum</em> and <em>Ocimum basilicum </em>on diabetic neuropathy (DN) has not been studied so far. So, the given manuscript was aimed to evaluate the effect of both plants by various in vitro biochemical parameters as well as <em>in vivo</em> studies.&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Methods:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> The given manuscript describes the effect of methanol extracts of <em>Ocimum sanctum</em> and <em>Ocimum basilicum</em>, in DN induced Swiss albino mice of either sex weighing 25-35 g. Mice were divided into 6 groups viz control (I) receiving citrate buffer, diabetic (II) and test groups (III, IV, V, VI) receiving streptozotocin at a dose of 100 mg/kg to induce DN on 21st day followed by treatment of test groups (III, IV, V, VI) at a dose of 100 mg/kg and 200 mg/kg daily for 14 days, with <em>Ocimum basilicum</em> and <em>Ocimum sanctum</em>, respectively.&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Results:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> The results showed that the methanol extracts of <em>Ocimum sanctum</em> and <em>Ocimum basilicum</em> gave significant change in weight variation, tail immersion test and blood glucose in comparison to diabetic control. In brain tissue homogenate measurement of oxidative stress by thiobarbituric acid reactive substance (TBARS), glutathione (GSH) and serum nitrite level, the methanol extract of both plants produced significant change when compared to diabetic control.</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Conclusion:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> This study underscores the promising role of herbal adjuncts in addressing the complexities of diabetic neuropathy and warrants continued investigation into their clinical utility.</span></p> 2025-02-27T22:03:49+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/53259 Neuroprotective Role of Ranolazine in Parkinson Disease: Drosophila Melanogaster Model 2025-02-28T15:01:13+01:00 Parvesh kaushikparvesh740@gmail.com Sandeep Kumar sranga118@gmail.com Govind Singh dr.govind.pharma@mdurohtak.ac.in Ramchander Khatri rckhatri@gmail.com Sunil Shukla sun.shulka5@gmail.com Kamal Kaushik kaushikkamal245@gmail.com Amit Lather dramitlather@gmail.com Tanuj Hooda tanujhooda2010@gmail.com <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Background/Aim:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Among the neurological ailments, Parkinson disease (PD) might be one of the most mysterious and intricate ones. The brain produces less dopamine as PD worsens, making it harder for a person to control their movements. In literature the effect of ranolazine (Rn) in the CNS has been proposed for the management of pain and epilepsy. So, it was hypothesised that ranolazine could act in neuroprotection. Aim of this study was to explore ranolazine effect in Parkinson and neuronal cells.&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Methods:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> <em>Drosophila melanogaster</em> has been employed. Five groups, each with 100 flies were: Group 1: control; Group 2: vehicle treated; Group 3: PD + ranolazine treated (1 mg/mL); Group 4: PD + ranolazine treated (2 mg/mL); Group-5: PD + ranolazine treated (4 mg/mL). PD was induced by paraquat. Part A involved the estimation of mortality index at 2-6 h. Estimation of climbing assay at 2 h, 4 h and 6 h and biochemical parameters such as oxidative stress were performed at 6 h.</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Results:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> At different concentration of ranolazine percentage climbing of flies was found improved. Ranolazine at dose of 4 mg/mL showed significant reduction in percentage mortality at 24 h. Ranolazine at dose of 4 mg/mL showed a significant effect on total protein content level. Ranolazine 1 mg/mL showed significant effect and 2 mg/mL showed significant reduction in superoxide dismutase (SOD) level as compared to vehicle group. Ranolazine 1 mg/mL, 2 mg/mL and 4 mg/mL showed significant reduction in malondialdehyde (MDA) level as compared to vehicle group.&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Conclusion:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> The present findings suggest that ranolazine has a good neuroprotective potential in the treatment of PD in flies. Further studies still required to be performed so as to explore its potential in clinical trials.</span></p> 2025-02-27T22:04:51+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/56050 Therapeutic Efficacy of Plant-Based Hydrogels in Burn Wound Healing: Focus on Satureja Montana L. and Origanum Vulgare L. 2025-03-11T22:42:29+01:00 Grigory A Demyashkin dr.dga@mail.ru Mikhail A Parshenkov misjakj@gmail.com Alibek A Tokov swimmishbrass9@gmail.com Tatiana P Sataieva tanzcool@mail.ru Ludmila A Shevkoplyas mila.shevckoplyas@yandex.ru Bekeev S Said saidov008@mail.ru Gasanbekov N Shamil Gasanbekov2001@yandex.ru <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Background/Aim:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Burn injuries present a critical issue for healthcare systems worldwide. They often lead to numerous complications, including persistent inflammation, impaired healing and heightened infection risks. The growing challenge of antibiotic resistance further complicates treatment, making bacterial infections harder to control and wound healing less effective. Existing treatment methods are often limited, highlighting the need for alternative approaches. Aim of this study was to analyse influence of hydrolate-based gels derived from <em>Satureja montana</em> L. and <em>Origanum vulgare</em> L. on the healing of burn wounds.&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Methods:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> New Zealand white rabbits (n = 25) with standardised Grade IIIa thermal burns were assigned to treatment groups receiving hydrolate-based gels (<em>Satureja montana</em> L. or <em>Origanum vulgare</em> L.), conventional therapy (<em>Betadine</em> (povidone-iodine) and <em>Levomecol</em> (methyluracil, chloramphenicol)), or no treatment. Inflammatory responses were tracked by collecting blood samples at the study&rsquo;s begin, on day 3 and at one- and two-weeks post-burn, with subsequent ELISA analysis. Histological evaluation of tissue regeneration and inflammatory response was conducted using haematoxylin and eosin staining on days 3, 7 and 14.&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Results:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> By day 14, <em>Satureja montana</em> L. demonstrated the most effective reduction in interleukin 6 (IL-6), tumour necrosis factor alpha (TNF-&alpha;) and C-reactive protein (CRP) levels, nearing baseline values. This biochemical improvement correlated with histological findings, showing advanced epithelial regeneration, reduced inflammatory cell infiltration and clearer dermal-epidermal boundaries. The results highlight <em>Satureja montana</em> L. as the most effective treatment in both inflammation control and tissue repair compared to <em>Origanum vulgare</em> L. and conventional therapy.&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Conclusion:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Hydrolate-based gels from <em>Satureja montana</em> L. and <em>Origanum vulgare</em> L. represent a promising option for adjunctive burn wound therapy. The <em>Satureja montana</em> L. group demonstrated significant improvements in inflammation control and tissue regeneration, while <em>Origanum vulgare</em> L. showed results comparable to standard therapy.</span></p> 2025-02-27T22:05:47+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/51703 Use of Psoriasis Epidemiology Screening Tool (PEST) to Identify Psoriatic Arthritis in Bosnia and Herzegovina 2025-03-11T22:45:42+01:00 Jelena Petković-Dabić jelena.petkovic81@yahoo.com Sanja Umičević-Šipka sanja.umicevic@kc-bl.com Sonja Barišić sonjabarisic04@gmail.com Saša Dabić sajodab@yahoo.com <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Background/Aim:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Psoriatic arthritis (PsA) is chronic inflammatory disease with estimated prevalence of 6 % to 41 % in patients with psoriasis. The aim of this study was to determine the prevalence of PsA in Bosnian patients with psoriasis in everyday dermatological practice by using psoriasis epidemiology screening tool (PEST) screening test for detection of PsA.</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Methods:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> This cross-sectional study included patients with a confirmed diagnosis of psoriasis. Data on patient demographics, clinical characteristics and treatment history, were collected using a questionnaire. Clinical characteristics of psoriasis included clinical cutaneous manifestations and plaques and psoriasis area and severity index (PASI). The risk of having PsA was evaluated by PEST (scores &ge; 3 indicate risk of PsA). The data were analysed using the Chi-square and Independent t-test.&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Results:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Of 79 included psoriatic patients, 22.8 % had a PEST &ge; 3. Psoriatic patients with PEST &ge; 3 were more likely to have certain comorbidities such as cardiovascular diseases (p = 0.044) and psychological disorders (p = 0.022). The psoriatic patients with PEST &lt; 3 and PEST &ge; 3 did not differ in PASI severity, but psoriatic patients with PEST &ge; 3 were more likely to have nail psoriasis (p &lt; 0.001).&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Conclusion:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> In the present study, using PEST questionnaire, one fifth of Bosnian patients were suspected of having PsA, highlighting a need for improved screening for PsA in daily dermatological practice. Earlier care is important because these patients were more likely to have cardiovascular diseases, psychological disorders and nail disease.</span></p> 2025-02-27T22:06:48+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/52070 Effect of Type 2 Diabetes Mellitus and Hypertension on Quality of Life: A Cross-Sectional Study 2025-02-28T15:01:13+01:00 Simran Goel rinammu@gmail.com Sristi Anupam rinammu@gmail.com Karun Bhatti rinammu@gmail.com Dinesh Kumar Mehta rinammu@gmail.com Rina Das rinammu@gmail.com <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Background/Aim:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> The quality of life (QOL) of the person is shown to be severely impacted by conditions such as type 2 diabetes mellitus (T2DM) and hypertension. Aim of this study was to investigate how both these conditions affect QOL of patients dealing with those conditions.&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Methods:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> A total of 276 participants were divided into three groups: T2DM (45.00 %), hypertension (14.75 %) and both conditions (40.25 %). The analysis included monitoring blood pressure and blood sugar levels. Participants completed a health quality evaluation questionnaire and data were expressed as mean &plusmn; standard deviation.&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Results:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> The results indicated that the duration of these diseases significantly impacted individuals' health. Physically, women were more adversely affected (12 %) than men (9.2 %) across all groups. Additionally, participants with mixed diets and both conditions experienced more negative effects (10.86 %) compared to vegetarians (6.25 %). It was found that individuals with T2DM and hypertension concurrently had a considerably lower QOL compared to those without these conditions.&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Conclusions:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> The study highlights that the type of diet and the duration of the disease significantly influence the QOL of patients. These factors were found to have a substantial impact on the overall well-being of individuals with T2DM and hypertension.</span></p> 2025-02-27T22:07:55+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/52353 Factors Associated With Paroxysmal Arrhythmias in Ambulatory ECG Monitored Patients 2025-03-11T22:49:39+01:00 Yusup Dwiyanto yusup.fik@gmail.com Tria Astika Endah Permatasari astika.tria@gmail.com Wati Jumaiyah watijumaiyah@gmail.com Siti Fadlilah sitifadlilah@respati.ac.id Sumarni Sumarni sumarnipkl@gmail.com <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Background/Aim:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Arrhythmia is a heart rhythm disorder that can appear suddenly without any symptoms and has the risk of causing other diseases and even death. This study aimed to determine predicting factors for the incidence of paroxysmal arrhythmias.</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Methods:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> This retrospective observational cohort study used patients' medical records in the Cardiovascular Outpatient Service Unit at RSUD Budhi Asih, Jakarta, Indonesia, from 2017-2021. Based on inclusion and exclusion criteria, 406 patients were analysed. The occurrence of paroxysmal arrhythmias based on the doctor's diagnosis in medical record data was divided into paroxysmal atrial, supraventricular, ventricular and atrioventricular block (AV block) arrhythmias. Data analysis used the Chi-square test.&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Results:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> A total of 39.4 % of patients had paroxysmal atrial arrhythmias. Factors associated with the occurrence of paroxysmal atrial arrhythmias were age, gender, smoking behaviour, comorbidities and heart-pumping ability. On the other hand, body mass index, hypertension and diabetes mellitus were shown to be significantly associated with paroxysmal supraventricular arrhythmias. Gender, smoking behaviour, diabetes mellitus, coronary heart disease, thyroid disease and heart pumping ability were predicting factors for paroxysmal ventricular arrhythmias. Meanwhile, only gender and heart disease were factors associated with paroxysmal AV block arrhythmias.</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Conclusion:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Sociodemographic and individual clinical conditions were associated with paroxysmal arrhythmias. However, these factors vary according to the outbreak of the arrhythmia.&nbsp;</span></p> 2025-02-27T22:09:39+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/52947 Antihypertensive Activities of Peronema Canescens Jack Extract: An In Vivo Study 2025-02-28T15:01:14+01:00 Muhammad Ma'ruf maruf@stikes-isfi.ac.id Moch Saiful Bachri msaifulbachri@yahoo.co.id Laela Hayu Nurani laelafarmasi@yahoo.com <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Background/Aim:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Hypertension commonly known as high blood pressure is characterised by a systolic readings of 140 mm Hg or higher and/or a diastolic readings of 90 mm Hg or above. Elevated blood pressure can lead to a heightened release of nitric oxide, a crucial factor in vascular relaxation. <em>Peronema canescens</em> Jack, commonly referred to as Sungkai, is known to contain flavonoids with antihypertensive properties and antioxidants that may help prevent cellular oxidation. This research aimed to evaluate the antihypertensive effects of ethanol extract from <em>Peronema canescens</em> Jack leaves and its impact on nitric oxide levels in hypertensive rats.</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Methods:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> This study used hypertensive male Wistar rats induced by NaCl (3.75 g/kg BW) and prednisone (1.5 mg/kg BW) administered orally. Blood pressure measurements were conducted using the non-invasive tail-cuff method and nitric oxide levels were analysed by reacting the sample with the Griess Reagent Assay.</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Results:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> The study's findings demonstrated a decrease in systolic, diastolic and mean arterial blood pressure, along with an increase in nitric oxide levels after administering ethanol extract of <em>Peronema canescens</em> Jack leaves (EEPC) at dosages of 50, 100 and 200 mg/kg BW. The most significant reduction in blood pressure was noted at the 100 and 200 mg/kg BW dosages (p &lt; 0.05), while the highest elevation in nitric oxide levels was observed at the 200 mg/kg BW dosage (p &lt; 0.05).</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Conclusion:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> The study concludes that administering the EEPC to hypertensive rats, induced by NaCl and prednisone, can lower blood pressure and elevate nitric oxide levels. These findings suggest that <em>Peronema canescens</em> Jack leaves hold potential as an antihypertensive agent.</span></p> 2025-02-27T22:10:46+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/53482 Intravascular Foreign Bodies Retrieval: Navigating Differences From Childhood to Adulthood 2025-02-28T15:01:14+01:00 Munaf Jarallah Yaseen manaf.j@comed.uobaghdad.edu.iq Nabeeha Najatee Akram nabiha@uomustansiriyah.edu.iq Wassan Nori dr.wassan76@uomustansiriyah.edu.iq <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Background/Aim:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> The increasing number of cardiovascular procedures is coupled with higher cardiovascular foreign bodies (FB) embolisation into the circulation. Aim of this study was to analyse centre&rsquo;s experience with percutaneous retrieval of FB, emphasising the differences between paediatrics and adults and highlighting failure-related parametres.&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Methods:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> A retrospective analysis of patients who underwent percutaneous retrieval FB in the heart and major blood vessels from February 2013 to April 2024 in the catheterisation lab at a specialised cardiovascular centre was performed. Data were subdivided into two groups: paediatric and adult. A collection was made of patient demographic and FB details, including type, site, the reason for introduction, duration of impaction, details of retrieval procedure including access site, types of catheters, device and sheath used, the time needed for extraction and whether the retrieval was successful.&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Results:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Twenty-two patients were included, 15 (68.2 %) adults and 7 (31.8 %) paediatric patients. The most common FB retrieved was a guide wire 7 (33 %) followed by an atrial septal occluder 6 (29 %). The right femoral artery was commonly accessed in both subgroups. Snare techniques were used in all patients. There were no complications or deaths reported. Overall procedure success was 18 cases (81.8 %), while the procedure failed in 4 (18.2 %) cases and those patients were referred to open surgery. No statistically significant differences were found between the patient&rsquo;s age, gender, the type of FB, the site of FB and the duration of FB impaction concerning the outcome of the procedure.&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Conclusion:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Percutaneous retrieval of cardiovascular FB is a safe, successful alternative to surgery. The success rate was comparable between adult and paediatric patients.</span></p> 2025-02-27T22:11:47+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/53332 Bone Marrow - Mesenchymal Stem Cell and Platelet Rich Fibrin: A Promising Step of Growth Plate Injury Treatment in Rabbit 2025-02-28T15:01:14+01:00 Dimas Rangga Yudyanda dimasrangga_02@yahoo.com Komang Agung Irianto komang168@yahoo.com Purwati Purwati purwati@fk.unair.ac.id <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Background/Aim:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Paediatric physeal injuries account for about 30 % of all bone injuries, often affecting growth plates. Current treatments emphasise prevention, as regenerating the damaged physis is challenging. This study aimed to analyse whether combining bone marrow mesenchymal stem-cell (BM-MSC) and platelet-rich fibrin (PRF) can regenerate physis bone.</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Methods:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> The twenty-four New Zealand white rabbits, aged 6 weeks, were acclimatised for 1 week. BM-MSC and PRF were then prepared. A physis injury was induced in the proximal tibia of the rabbits, then divided into four groups: control, BM-MSC treatment, PRF treatment, combination of BM-MSC and PRF treatment. After 4 weeks, rabbits were sacrificed and evaluated. The bony bar diameter was measured using haematoxylin-eosin (H&amp;E) staining, while the expression of tumour necrosis factor-alpha (TNF-&alpha;), vascular endothelial growth factor (VEGF) and SRY-box transcription factor 9 (SOX-9) was evaluated using immunohistochemistry (IHC).&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Results:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Histology showed that the BM-MSC and PRF combination led to better regeneration than the control, BM-MSC alone, or PRF alone in terms of osteochondral union. SOX-9 indicators showed significant differences between the control vs BM-MSC groups (p = 0.099); BM-SC vs PRF groups (p = 0.032). TNF-&alpha; indicators showed no significant differences at all. VEGF indicators showed significant differences between the control vs BM-MSC and PRF groups (p = 0.008); PRF vs BM-MSC and PRF groups (p = 0.021).</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Conclusion:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Administration of BM-MSC, PRF or a combination of BM-MSC and PRF showed comparable effectiveness in osteochondral union based on histological outcomes. Conversely, PRF alone exhibited the highest effectiveness in IHC analysis. However, none of these results were statistically significant.</span></p> 2025-02-27T22:13:19+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/52374 Implementation of a Patient Safety Policy in Hospitalisation of Surgical Cases 2025-02-28T15:01:15+01:00 Rina Budi Kristiani rinabudikristiani.rb@gmail.com Chindy Maria Orizani chindy@adihusada.ac.id Iswati Iswati iswatisaja@gmail.com Siti Nur Qomariah snurq18@gmail.com Abu Bakar abu.bakar@fkp.unair.ac.id Sosilo Yobel syobel@gmail.com <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Background/Aim:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> The Seven Steps to Patient Safety is a reference guide for hospitals implementing a patient safety program. The seven steps are building awareness of the value of patient safety, leading and supporting staff, integrating risk reporting activities, developing reporting systems, involving and communicating with patients, learning and sharing experiences about patient safety and preventing injuries through the implementation of patient safety systems. The purpose of this study was to evaluate the implementation of a patient safety policy in the hospitalisation of surgical medical cases.</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Methods:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> In this cross-sectional research, 360 nurses from several Gresik City public and private hospitals participated. Questionnaires on the application of the patient safety policy and a questionnaire that modified the seven steps of patient safety as implemented by nurses in the medical-surgical inpatient wards were used as the study instruments. Multiple logistic regression analysis was used to examine the data.</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Results:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Most nurses have worked in medical-surgical for 6-10 years with work hours 40-59 every week. Implementation of patient safety had negative responses from nurses in Step 3 (integrated risk management) and Step 5 (open communication to patients and families). The simple logistic regression results for all steps were significant. Therefore, multiple logistic regression has shown that steps 1, 2, 4, 6 and 7 were significant to the implementation of patient safety policies.</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Conclusions:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Patient safety policy remains a shared commitment that needs to be implemented. Hospitals as healthcare institutions that directly treat patients must prioritise safe, quality, anti-discriminatory and effective health services, prioritising the interests of patients according to hospital service standards.</span></p> 2025-02-27T22:14:36+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/52683 Secondary Failure of Oral Therapy in Patients With Type 2 Diabetes - How To Overcome It? 2025-02-28T15:01:15+01:00 Aleksandra Marković aleksandra.markovic@med.unibl.org Tamara Dojčinović taca.knezevic88@gmail.com Ivona Risović ivona.risovic@gmail.com Milorad Grujičić grujicic-m@hotmail.com Jelena Malinović Pančić malinovic_jelena@yahoo.com <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Background/Aim:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Secondary failure of oral therapy occurs after a long period of successful use of oral antidiabetic drugs. The exact mechanism of its occurrence is not known. Recent data suggest heterogeneity of this phenomenon, analogous that of type 2 diabetes pathogenesis. Research objective was to assess glucoregulation and insulin secretory function before, three months after the use of insulin therapy and three months after the exclusion and re-introduction of oral antidiabetic therapy.</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Methods:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Forty-nine patients with unsatisfactory glycaemic control were selected and insulin therapy in four daily doses (basal-bolus regimen) was subsequently initiated. Glycaemic regulation and beta cell function (C-peptide and insulinemia) were monitored at three time points: before starting insulin therapy, three months after initiating insulin and three months after discontinuing insulin and resuming the previously used oral antidiabetics.</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Results:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> After the introduction of insulin therapy, there was a significant improvement in glycaemic regulation parameters (p &lt; 0.001). Improvements in beta-cell function and reductions in insulin resistance were confirmed during the period after insulin therapy (p &lt; 0.001). However, a certain deterioration in these parameters was observed following the discontinuation of insulin therapy. Additionally, there was a slight decrease in C-peptide and an increase in insulinemia, though these changes were not statistically significant.</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Conclusion: </span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Application of intensified insulin therapy for three months leads to improvement of glucoregulation and partial recovery of the secretory function of the endocrine pancreas. The reintroduction of oral antidiabetic therapy led to a slight worsening of the observed parameters, although this change was not statistically significant.&nbsp;</span></p> 2025-02-27T22:15:31+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/55643 Association of GPX1 Pro198Leu and SOD1 A251G Polymorphisms With Risk of Acute Kidney Rejection 2025-02-28T15:01:15+01:00 Shima Rayatpisheh shima.rayat@gmail.com Mohammad-Hossein Karimi karimi70@yahoo.com Iraj Saadat isaadat@shirazu.ac.ir <p><!-- [if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:TrackMoves/> <w:TrackFormatting/> <w:PunctuationKerning/> <w:ValidateAgainstSchemas/> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <w:DoNotPromoteQF/> <w:LidThemeOther>EN-US</w:LidThemeOther> <w:LidThemeAsian>X-NONE</w:LidThemeAsian> <w:LidThemeComplexScript>FA</w:LidThemeComplexScript> <w:Compatibility> <w:BreakWrappedTables/> <w:SnapToGridInCell/> <w:WrapTextWithPunct/> <w:UseAsianBreakRules/> <w:DontGrowAutofit/> <w:SplitPgBreakAndParaMark/> <w:EnableOpenTypeKerning/> <w:DontFlipMirrorIndents/> <w:OverrideTableStyleHps/> </w:Compatibility> <m:mathPr> <m:mathFont m:val="Cambria Math"/> <m:brkBin m:val="before"/> <m:brkBinSub m:val="&#45;-"/> <m:smallFrac m:val="off"/> <m:dispDef/> <m:lMargin m:val="0"/> <m:rMargin m:val="0"/> <m:defJc m:val="centerGroup"/> <m:wrapIndent m:val="1440"/> <m:intLim m:val="subSup"/> <m:naryLim m:val="undOvr"/> </m:mathPr></w:WordDocument> </xml><![endif]--><!-- [if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="false" DefSemiHidden="false" DefQFormat="false" DefPriority="99" LatentStyleCount="371"> <w:LsdException Locked="false" Priority="0" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 6"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 7"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 8"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 9"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 9"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Normal Indent"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="footnote text"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="annotation text"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="header"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="footer"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index heading"/> <w:LsdException Locked="false" Priority="35" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="caption"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="table of figures"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="envelope address"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="envelope return"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="footnote reference"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="annotation reference"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="line number"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="page number"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="endnote reference"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="endnote text"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="table of authorities"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="macro"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="toa heading"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Bullet"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Number"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Bullet 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Bullet 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Bullet 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Bullet 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Number 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Number 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Number 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Number 5"/> <w:LsdException Locked="false" Priority="10" QFormat="true" Name="Title"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Closing"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Signature"/> <w:LsdException Locked="false" Priority="1" SemiHidden="true" UnhideWhenUsed="true" Name="Default Paragraph Font"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text Indent"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Continue"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Continue 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Continue 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Continue 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Continue 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Message Header"/> <w:LsdException Locked="false" Priority="11" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Salutation"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Date"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text First Indent"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text First Indent 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Note Heading"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text Indent 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text Indent 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Block Text"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Hyperlink"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="FollowedHyperlink"/> <w:LsdException Locked="false" Priority="22" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Document Map"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Plain Text"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="E-mail Signature"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Top of Form"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Bottom of Form"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Normal (Web)"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Acronym"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Address"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Cite"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Code"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Definition"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Keyboard"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Preformatted"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Sample"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Typewriter"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Variable"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Normal Table"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="annotation subject"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="No List"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Outline List 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Outline List 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Outline List 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Simple 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Simple 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Simple 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Classic 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Classic 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Classic 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Classic 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Colorful 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Colorful 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Colorful 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Columns 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Columns 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Columns 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Columns 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Columns 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 6"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 7"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 8"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 6"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 7"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 8"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table 3D effects 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table 3D effects 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table 3D effects 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Contemporary"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Elegant"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Professional"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Subtle 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Subtle 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Web 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Web 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Web 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Balloon Text"/> <w:LsdException Locked="false" Priority="39" Name="Table Grid"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Theme"/> <w:LsdException Locked="false" SemiHidden="true" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" Name="Light List"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" SemiHidden="true" Name="Revision"/> <w:LsdException Locked="false" Priority="34" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" SemiHidden="true" UnhideWhenUsed="true" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="TOC Heading"/> <w:LsdException Locked="false" Priority="41" Name="Plain Table 1"/> <w:LsdException Locked="false" Priority="42" Name="Plain Table 2"/> <w:LsdException Locked="false" Priority="43" Name="Plain Table 3"/> <w:LsdException Locked="false" Priority="44" Name="Plain Table 4"/> <w:LsdException Locked="false" Priority="45" Name="Plain Table 5"/> <w:LsdException Locked="false" Priority="40" Name="Grid Table Light"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light Accent 1"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 1"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 1"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 1"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 1"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful Accent 1"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful Accent 1"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light Accent 2"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 2"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 2"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 2"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 2"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful Accent 2"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful Accent 2"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light Accent 3"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 3"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 3"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 3"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 3"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful Accent 3"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful Accent 3"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light Accent 4"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 4"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 4"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 4"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 4"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful Accent 4"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful Accent 4"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light Accent 5"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 5"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 5"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 5"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 5"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful Accent 5"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful Accent 5"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light Accent 6"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 6"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 6"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 6"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 6"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful Accent 6"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful Accent 6"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light Accent 1"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 1"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 1"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 1"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 1"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful Accent 1"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful Accent 1"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light Accent 2"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 2"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 2"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 2"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 2"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful Accent 2"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful Accent 2"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light Accent 3"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 3"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 3"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 3"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 3"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful Accent 3"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful Accent 3"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light Accent 4"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 4"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 4"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 4"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 4"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful Accent 4"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful Accent 4"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light Accent 5"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 5"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 5"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 5"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 5"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful Accent 5"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful Accent 5"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light Accent 6"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 6"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 6"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 6"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 6"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful Accent 6"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful Accent 6"/> </w:LatentStyles> </xml><![endif]--><!-- [if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0in; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:Arial; mso-bidi-theme-font:minor-bidi;} </style> <![endif]--></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Background/Aim:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Acute rejection is one factor threatening the success of kidney transplantation. One of the factors that can cause graft rejection is oxidative stress. The aim of this study was to investigate the association between <em>GPX1</em> Pro198Leu and <em>SOD1</em> A251G polymorphisms and acute renal allograft rejection.</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Methods:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> A total of 262 healthy individuals and 262 patients who had undergone kidney transplantation were enrolled in the present study, of which 46 patients had acute rejection. The genotypes were determined using the PCR-RFLP technique. Case-control study between patients and control groups and cohort study between patients with and without acute rejection were then performed.&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Results:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> Analysis showed that the incidence of kidney disease leading to kidney transplantation did not depend on the genotype of <em>GPX1</em> and <em>SOD1</em> polymorphisms. In the cohort study, no significant differences were observed between the cases with and without acute rejection for any of the two genes.</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Conclusions:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> The genotypes of <em>GPX1</em> and <em>SOD1</em> polymorphisms were not found to be involved in the incidence of acute renal rejection. It is advised to continue further studies, because defects in the activities of these genes can be compensated by other members of their families.</span></p> 2025-02-27T22:16:41+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/54562 No Evidence for an Association Between the Chemokine Receptor 5 Δ32 Polymorphism and Multiple Sclerosis Susceptibility: A Meta-Analysis 2025-02-28T15:01:16+01:00 Nazanin Akbari na.akbari7676@gmail.com Mostafa Saadat saadat@shirazu.ac.ir <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; letter-spacing: -.15pt; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Background/Aim: </span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; letter-spacing: -.15pt; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Numerous reports have been published on the association of the chemokine receptor 5 &Delta;32 genetic variation (rs333) with the risk of multiple sclerosis (MS), with results that are inconsistent. The relationship between rs333 and susceptibility to MS was evaluated in this study.</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; letter-spacing: -.15pt; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Methods:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; letter-spacing: -.15pt; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> The PRISMA guidelines were followed in the current study. Twelve databases were used to find eligible articles. The investigators extracted the necessary information. The associations of the alleles and genotypes were evaluated in different models of inheritance: co-dominant, dominant and recessive genotype models and allele model.</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; letter-spacing: -.15pt; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Results:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; letter-spacing: -.15pt; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> The analysis included 14 articles reporting 16 studies involving 3265 MS patients and 3735 healthy controls. There was no substantial heterogeneity between studies for any of the comparisons. The significance level was not reached for the association between rs333 and MS susceptibility.&nbsp;</span></p> <p class="MsoNormal" style="text-align: justify;"><strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; letter-spacing: -.15pt; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Conclusion:</span></strong><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; letter-spacing: -.15pt; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> The findings of this study could not confirm the relationship between the rs333 and susceptibility to multiple sclerosis.</span></p> <p class="MsoNormal" style="text-align: justify;"><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">&nbsp;</span></p> 2025-02-27T22:18:05+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/56443 Molecular Mechanisms for Pathophysiology and Therapy of Cardiac Dysfunction in Heart Failure 2025-03-11T22:52:18+01:00 Naranjan S Dhalla nsdhalla@sbrc.ca Vijayan Elimban VElimban@sbrc.ca Adriana Duris Adameova adriana.duris.adameova@uniba.sk Ramesh K Goyal goyalrk@gmail.com <p><!-- [if gte mso 9]><xml> <o:OfficeDocumentSettings> <o:RelyOnVML/> <o:AllowPNG/> </o:OfficeDocumentSettings> </xml><![endif]--><!-- [if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:TrackMoves/> <w:TrackFormatting/> <w:PunctuationKerning/> <w:ValidateAgainstSchemas/> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <w:DoNotPromoteQF/> <w:LidThemeOther>EN-US</w:LidThemeOther> <w:LidThemeAsian>X-NONE</w:LidThemeAsian> <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript> <w:Compatibility> <w:BreakWrappedTables/> <w:SnapToGridInCell/> <w:WrapTextWithPunct/> <w:UseAsianBreakRules/> <w:DontGrowAutofit/> <w:SplitPgBreakAndParaMark/> <w:EnableOpenTypeKerning/> <w:DontFlipMirrorIndents/> <w:OverrideTableStyleHps/> </w:Compatibility> <m:mathPr> <m:mathFont m:val="Cambria Math"/> <m:brkBin m:val="before"/> <m:brkBinSub m:val="&#45;-"/> <m:smallFrac m:val="off"/> <m:dispDef/> <m:lMargin m:val="0"/> <m:rMargin m:val="0"/> <m:defJc m:val="centerGroup"/> <m:wrapIndent m:val="1440"/> <m:intLim m:val="subSup"/> <m:naryLim m:val="undOvr"/> </m:mathPr></w:WordDocument> </xml><![endif]--><!-- [if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="false" DefSemiHidden="false" DefQFormat="false" DefPriority="99" LatentStyleCount="375"> <w:LsdException Locked="false" Priority="0" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 6"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 7"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 8"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 9"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 9"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Normal Indent"/> <w:LsdException Locked="false" Priority="0" SemiHidden="true" UnhideWhenUsed="true" Name="footnote text"/> <w:LsdException Locked="false" Priority="0" SemiHidden="true" UnhideWhenUsed="true" Name="annotation text"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="header"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="footer"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index heading"/> <w:LsdException Locked="false" Priority="35" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="caption"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="table of figures"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="envelope address"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="envelope return"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="footnote reference"/> <w:LsdException Locked="false" Priority="0" SemiHidden="true" UnhideWhenUsed="true" Name="annotation reference"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="line number"/> <w:LsdException Locked="false" Priority="0" SemiHidden="true" UnhideWhenUsed="true" Name="page number"/> <w:LsdException Locked="false" Priority="0" SemiHidden="true" UnhideWhenUsed="true" Name="endnote reference"/> <w:LsdException Locked="false" Priority="0" SemiHidden="true" UnhideWhenUsed="true" Name="endnote text"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="table of authorities"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="macro"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="toa heading"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Bullet"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Number"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Bullet 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Bullet 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Bullet 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Bullet 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Number 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Number 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Number 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Number 5"/> <w:LsdException Locked="false" Priority="10" QFormat="true" Name="Title"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Closing"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Signature"/> <w:LsdException Locked="false" Priority="1" SemiHidden="true" UnhideWhenUsed="true" Name="Default Paragraph Font"/> <w:LsdException Locked="false" Priority="0" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text Indent"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Continue"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Continue 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Continue 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Continue 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Continue 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Message Header"/> <w:LsdException Locked="false" Priority="11" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Salutation"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Date"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text First Indent"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text First Indent 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Note Heading"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text Indent 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text Indent 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Block Text"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Hyperlink"/> <w:LsdException Locked="false" Priority="0" SemiHidden="true" UnhideWhenUsed="true" Name="FollowedHyperlink"/> <w:LsdException Locked="false" Priority="22" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Document Map"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Plain Text"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="E-mail Signature"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Top of Form"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Bottom of Form"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Normal (Web)"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Acronym"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Address"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Cite"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Code"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Definition"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Keyboard"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Preformatted"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Sample"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Typewriter"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Variable"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Normal Table"/> <w:LsdException Locked="false" Priority="0" SemiHidden="true" UnhideWhenUsed="true" Name="annotation subject"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="No List"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Outline List 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Outline List 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Outline List 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Simple 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Simple 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Simple 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Classic 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Classic 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Classic 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Classic 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Colorful 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Colorful 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Colorful 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Columns 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Columns 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Columns 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Columns 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Columns 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 6"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 7"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 8"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 6"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 7"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 8"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table 3D effects 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table 3D effects 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table 3D effects 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Contemporary"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Elegant"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Professional"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Subtle 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Subtle 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Web 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Web 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Web 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Balloon Text"/> <w:LsdException Locked="false" Priority="59" Name="Table Grid"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Theme"/> <w:LsdException Locked="false" SemiHidden="true" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" Name="Light List"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" SemiHidden="true" Name="Revision"/> <w:LsdException Locked="false" Priority="34" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" SemiHidden="true" UnhideWhenUsed="true" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="TOC Heading"/> <w:LsdException Locked="false" Priority="41" Name="Plain Table 1"/> <w:LsdException Locked="false" Priority="42" Name="Plain Table 2"/> <w:LsdException Locked="false" Priority="43" Name="Plain Table 3"/> <w:LsdException Locked="false" Priority="44" Name="Plain Table 4"/> <w:LsdException Locked="false" Priority="45" Name="Plain Table 5"/> <w:LsdException Locked="false" Priority="40" Name="Grid Table Light"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light Accent 1"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 1"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 1"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 1"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 1"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful Accent 1"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful Accent 1"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light Accent 2"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 2"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 2"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 2"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 2"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful Accent 2"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful Accent 2"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light Accent 3"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 3"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 3"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 3"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 3"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful Accent 3"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful Accent 3"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light Accent 4"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 4"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 4"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 4"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 4"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful Accent 4"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful Accent 4"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light Accent 5"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 5"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 5"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 5"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 5"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful Accent 5"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful Accent 5"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light Accent 6"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 6"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 6"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 6"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 6"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful Accent 6"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful Accent 6"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light Accent 1"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 1"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 1"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 1"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 1"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful Accent 1"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful Accent 1"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light Accent 2"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 2"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 2"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 2"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 2"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful Accent 2"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful Accent 2"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light Accent 3"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 3"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 3"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 3"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 3"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful Accent 3"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful Accent 3"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light Accent 4"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 4"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 4"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 4"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 4"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful Accent 4"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful Accent 4"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light Accent 5"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 5"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 5"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 5"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 5"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful Accent 5"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful Accent 5"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light Accent 6"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 6"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 6"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 6"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 6"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful Accent 6"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful Accent 6"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Mention"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Smart Hyperlink"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Hashtag"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Unresolved Mention"/> </w:LatentStyles> </xml><![endif]--><!-- [if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:8.0pt; mso-para-margin-left:0in; line-height:107%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;} </style> <![endif]--></p> <p class="MsoNormal" style="text-align: justify;"><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Extensive work over the past 6 decades in the field of cardiovascular medicine has revealed that haemodynamic, hormonal, metabolic, cellular and molecular mechanisms of heart failure are not only complex but are also dependent upon the type and stage of heart disease. Although various agents such as &beta;-adrenoreceptor blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists and vasodilators are available for the treatment of heart failure, these interventions delay the progression of heart failure without reducing mortality and morbidity. In this article, literature on the pathophysiology of heart failure due to myocardial infarction and haemodynamic overload to identify molecular targets for future drug development is reviewed. Particularly, objective was to focus on the mechanisms of heart failure involving pathways for the generation of oxidative stress, myocardial inflammation and Ca<sup>2+</sup>-handling abnormalities. It is evident that elevated levels of plasma vasoactive hormones and growth factors as well as increased preload and afterload play critical roles in stimulating various signal transduction pathways for the occurrence of increased ventricular wall stress, cardiac remodelling and subsequent cardiac dysfunction. These alterations are associated with development of oxidative stress, myocardial inflammation, endothelial dysfunction, metabolic defects, intracellular Ca<sup>2+</sup>-handling abnormalities, apoptosis, fibrosis and changes in the extracellular matrix. In view of such pathogenic abnormalities in failing hearts, it is suggested these parameters may serve as excellent targets for drug development for the therapy of heart failure. In addition, there occurs activation of proteases and phospholipases as well as depression in cardiac gene expression for the induction of subcellular remodelling in failing hearts and thus interventions affecting these parameters may also be considered to exert beneficial effects in heart failure. There is also an urgent need to develop some existing and newer agents such as metabolic inhibitors, antioxidants and sodium-glucose cotransporter-2 inhibitors as well as gene and RNA based therapies for the treatment of heart failure.</span></p> 2025-02-27T22:19:17+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/53169 Diverse Routes in the Development of Obesity 2025-02-28T15:01:16+01:00 Preeti preetiminhas63@gmail.com Rahul Kumar Sharma buntyrahul177@gmail.com Shivani Chopra shanuvashisht2730@gmail.com Hitesh Chopra chopraontheride@gmail.com <p style="text-align: justify;"><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">Obesity, a prevalent community health concern, is a diseased state characterised by an abundance of adipose tissue. This condition arises from notable transformations resulting from modern civilisation, where overconsumption and sedentary behaviours have become commonplace in contemporary society. Obesity&rsquo;s prevalence and associated health effects present a significant public health challenge affecting both physical and cognitive health and executive function impairments are commonly observed. In obese individuals, suggesting a complex interplay between weight and cognitive well-being, the gut microbiota serves as a bridge between external factors like diet and lifestyle and the body&rsquo;s physiological processes, potentially illuminating the intricate pathways connecting these health issues. Unhealthy dietary patterns characteristic of Western diets contributes to imbalances in the gut microbiota, which can exacerbate obesity-related complications. Research indicates that the gut microbiota linked to obesity may instigate various changes in the body, including disruptions in the hypothalamic-pituitary-adrenal axis. These disruptions can lead to disturbances in hormone regulation, desensitisation of leptin receptors, resistance and neuroinflammation. It is crucial to grasp the interplay between altered the hypothalamic-pituitary-adrenal (HPA) axis activity and long-term consequences of obesity, considering factors like age, gender and racial disparities. Examining the intricate connection between neuro-immunology and immune metabolism, particularly in adipose tissue where immune cells and the sympathetic nervous system (SNS) play crucial roles, can provide insights into the complex mechanisms of obesity-related health issues. This review emphasises the multifaceted mechanisms in the development of obesity, laying the groundwork for understanding various avenues that could be explored for innovative and effective pharmaceutical interventions in obesity management.</span></p> 2025-02-27T22:20:16+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/52551 Nanoparticle-Based Drug Delivery Systems: A Promising Approach for Targeted Ulcerative Colitis Therapy 2025-02-28T15:01:17+01:00 Neha Tanwar drneharaj28@gmail.com Loveleen Kaur Loveleen.kaur@chitkara.edu.in Hitesh Chopra chopraontheride@gmail.com <p class="MsoNormal" style="text-align: justify;"><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Inflammatory bowel disease (IBD), includes ulcerative colitis (UC) and Crohn's disease (CD), is characterised by recurrent, chronic inflammation of the gastrointestinal system. For the treatment of UC, oral medication delivery to the colon is largely favoured since it increases their effectiveness while lowering systemic toxicity. To deliver oral a medication to the colon, which is at the distal end of the gastrointestinal system is however challenging, because of physiological difficulties, biochemical barriers and environmental obstacles, such as those brought on by mucus and epithelium. Recent preclinical studies have suggested that targeted medication administration to the colon using nanoparticle-based drug delivery systems (DDS) may be a promising strategy for the treatment of UC. Additionally, this study offers a thorough assessment of newly discovered naturally produced nanoparticles (such as extracellular vesicles and plant-derived nanoparticles) as well as DDS based on synthetic nanoparticles. These innovative UC treatment plans based on nanoparticles may present a chance for the clinical application of nanoparticle formulae.</span></p> 2025-02-27T22:21:14+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/55876 Heat Shock Protein 60 in Vascular Biology 2025-03-11T22:56:22+01:00 Thomas E Hedley thedley@sbrc.ca Justin F Deniset jdeniset@sbrc.ca Andrew A Francis afrancis@sbrc.ca Grant N Pierce gpierce@sbrc.ca <p class="MsoNormal" style="text-align: justify;"><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">The response of heat shock proteins (HSPs) to stress-induced stimuli is now well documented and understood. Specific HSPs like HSP70 play an important role in vascular diseases like atherosclerosis and hypertension. However, the involvement of other HSPs in these vascular pathologies has been largely ignored. HSP60 plays a particularly critical role in vascular cell growth, an important component of many vascular pathologies. HSP60 directly induces vascular smooth muscle cell proliferation. The mechanism may involve an HSP60-induced stimulation of the rate of nuclear protein import in the smooth muscle cell. HSP60 expression levels also correlate with the severity of the disease. In conclusion, HSP60 may have an important role to play in vascular diseases like atherosclerosis. HSP60 may be a promising future pharmaceutical target to focus upon in order to deter the pathological effects of disease conditions like hypertension and atherosclerosis.</span></p> <p class="MsoNormal" style="text-align: justify;"><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">&nbsp;</span></p> 2025-02-27T22:22:20+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/52565 Overview of Monkeypox Virus 2025-03-11T23:01:33+01:00 Kashish Wilson kashishwilson02@mmumullana.org Garima garima.malik@mmumullana.org Rajat Goyal rajatgoyal338@gmail.com Hitesh Chopra chopraontheride@gmail.com Shivani Chopra shanuvashisht2730@gmail.com Meenakshi Dhanawat meenakshi.itbhu@gmail.com <p class="MsoNormal" style="text-align: justify;"><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Monkeypox virus (MPXV) is a close relative of the Variola (smallpox) virus, which was formerly prevalent throughout West and Central Africa. Nonetheless, instances have lately been verified outside of Africa in several nonendemic nations. Considering the COVID-19 pandemic, the World Health Organization (WHO) defined the recent monkeypox spread health emergency for the public for global significance on 23 July 2022. This worldwide community may be in danger because of the increased number of confirmed cases. The monkeypox virus (MPXV), the etiologic agent, was isolated from diseased monkeys in 1959, and its pathogenicity in humans was first documented in the 1970s, primarily in Western and Central African endemic countries. But in 2022, this disease shows extreme return at a never-before-seen rate, raising concerns about its communicative expansion in non-endemic areas and its potential for human-to-human transmission. Healthcare professionals, public health regulators and the general people around the world must possess substantial expertise for such relatively unknown viral diseases to mitigate the situation. Here, a thorough and current pathogenesis overview, epidemiology and clinical characteristics, along with monkeypox therapy is presented. This current review also covers future research fields, vaccine advancements and preventive and control methods for this reemerging viral disease that is currently recognised as a global crisis in public health.</span></p> 2025-02-27T22:23:28+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/54471 Dysthanasia 2025-03-11T23:04:06+01:00 Alen Greš alengres@gmail.com Dijana Staver staver.dijana@gmail.com Ljubomir Radovančević ljubomir.radovancevic@gmail.com <p class="MsoNormal" style="text-align: justify;"><em><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Dysthanasia</span></em><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;"> in medicine is the artificial prolongation and delay of death in a terminal patient, using all available means. With the advancement of sophisticated medical technologies and care, the patient can be kept alive as long as possible in the terminal stages of the disease. Such a procedure brings little benefit to the patient, while increasing suffering and sorrow for the patient and their families. The ethical implications of using medical technology in <em>dysthanasia</em> are complex. The challenge lies in the ethical and judicious use of modern technologies to respect the dignity and wishes of patients while avoiding unnecessary suffering.</span></p> <p class="MsoNormal" style="text-align: justify;"><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">&nbsp;</span></p> 2025-02-27T22:24:33+01:00 Copyright (c) 2025 Scripta Medica https://aseestant.ceon.rs/index.php/scriptamed/article/view/53460 Paediatric Post-Traumatic Tenosynovial Chondromatosis of the Foot: A Case Report 2025-03-11T23:07:06+01:00 Šemsudin Porčić semsudin.porcic@gmail.com Andrej Jokić andrejjokic73@gmail.com Irma Todorovac Hodžić irmatodorovac96@gmail.com <div class="page" title="Page 2"> <div class="layoutArea"> <div class="column"> <p class="MsoNormal" style="text-align: justify;"><span lang="EN-GB" style="font-size: 11.0pt; font-family: 'Helvetica Neue LT Pro'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;">Tenosynovial chondromatosis (TC) is a rare benign condition characterised by the formation of cartilaginous nodules from tendon sheaths or articular membranes. It primarily affects the hand and wrist structures. The condition predominantly affects individuals in their thirties to fifties. The post-traumatic TC is not reported in a paediatric patient, to the best of our knowledge. The purpose of this case was to describe a five-year-old girl's case of TC, which had a highly unusual localisation in the foot following a post-traumatic event. In order to handle this challenging lesion, the clinical presentation, imaging modalities, histopathology and surgical treatment is presented. Performing surgery with wide margins is the gold standard.</span></p> </div> </div> </div> 2025-02-27T22:25:46+01:00 Copyright (c) 2025 Scripta Medica